A Phase I Study of Everolimus and Docetaxel in Patients With Castration-Resistant Prostate Cancer
Courtney K, Manola J, Elfiky A, Ross R, Oh W, Yap J, Van den Abbeele A, Ryan C, Beer T, Loda M, Priolo C, Kantoff P, Taplin M. A Phase I Study of Everolimus and Docetaxel in Patients With Castration-Resistant Prostate Cancer. Clinical Genitourinary Cancer 2014, 13: 113-123. PMID: 25450031, PMCID: PMC4418946, DOI: 10.1016/j.clgc.2014.08.007.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorDocetaxelDrug Administration ScheduleEverolimusFluorodeoxyglucose F18HumansMaleMaximum Tolerated DoseMiddle AgedPositron-Emission TomographyProstatic Neoplasms, Castration-ResistantTaxoidsTreatment OutcomeConceptsProstate-specific antigenPartial metabolic responseFDG-PETMTOR inhibitorsFDG-PET/computed tomography scansProstate-specific antigen reductionTolerability of combination therapyCastration-resistant prostate cancerActivation of AKT-mTOR signalingFDG-PET responseLevels of everolimusStable metabolic diseaseResponse to everolimusPhase I studyPhase I trialMetabolic diseasesProgressive metabolic diseaseConcentrations of everolimusAkt-mTOR signalingCRPC patientsCombination therapyI trialProstate cancerTomography scanPatient cohort
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply